Eyesight news and eyesight widget

Lpath, Inc. (OTCBB: LPTN) today announced that the laboratory of Peter Campochiaro, MD at Johns Hopkins University School of Medicine(1) recently published peer-reviewed findings of a research study of iSONEP(TM), Lpath's Phase 1 anti-S1P antibody, demonstrating promising results in various animal models of ocular disorders. The findings of the study appeared online ahead of print in the

Title: Blood Sugar Control Helps Diabetics Preserve SightCategory: health newscreated: 11/15/2008 2:00:00 amlast Editorial review: 11/17/2008